[Antibody-mediated proteolysis of myelin-associated proteins as a new mechanism of control over demyelinization processes in multiple sclerosis].
Natural antibodies possessing catalytic activity present a new group of biologically active substances that are found in various autoimmune diseases such as autoimmune thyroiditis, myocarditis, multiple sclerosis, and system lupus erythematosus. Presently, an interconnection between the activity of these antibodies and the extent of organic and tissue lesion in autoaggression have been revealed. Clinical use of catalytic antibodies as a diagnostic criterion to evaluate the severity of disease, a prognostic criterion of the risk of invalidization, and as a pathogenetic basis for medicamentous treatment of autoimmune process is a promising directions of study of the role of catalytic antibodies.
Suchkov
S V
SV
Vvedenskaia
O Iu
OIu
Vostrikova
I L
IL
Gabibov
A G
AG
Kimova
M V
MV
Burdakova
Iu A
IuA
Ponomarenko
N A
NA
Pal'tsev
M A
MA
D017151:Antibodies, Catalytic; D018450:Disease Progression; D006801:Humans; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000276:immunology / Q000378:metabolism; D018992:Myelin-Associated Glycoprotein / Q000276:immunology* / Q000378:metabolism; D009413:Nerve Fibers, Myelinated / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D012720:Severity of Illness Index
D017151:Antibodies, Catalytic; D018992:Myelin-Associated Glycoprotein